Mallinckrodt PLC (MNK) Short Interest Update
Mallinckrodt PLC (NYSE:MNK) was the target of a large growth in short interest during the month of February. As of February 15th, there was short interest totalling 29,377,082 shares, a growth of 18.5% from the January 31st total of 24,787,756 shares. Approximately 31.2% of the shares of the company are sold short. Based on an average daily volume of 3,408,198 shares, the days-to-cover ratio is currently 8.6 days.
Shares of Mallinckrodt (NYSE MNK) opened at $16.31 on Monday. Mallinckrodt has a twelve month low of $15.27 and a twelve month high of $52.92. The company has a current ratio of 2.18, a quick ratio of 1.05 and a debt-to-equity ratio of 0.98. The firm has a market capitalization of $1,408.37, a price-to-earnings ratio of 0.72, a PEG ratio of 0.33 and a beta of 1.06.
Mallinckrodt (NYSE:MNK) last posted its earnings results on Tuesday, February 27th. The company reported $2.01 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.72 by $0.29. Mallinckrodt had a return on equity of 13.43% and a net margin of 66.25%. The company had revenue of $792.30 million during the quarter, compared to the consensus estimate of $769.91 million. During the same quarter last year, the firm earned $1.91 earnings per share. The company’s revenue was down 4.5% on a year-over-year basis. research analysts forecast that Mallinckrodt will post 6.21 EPS for the current fiscal year.
Several institutional investors and hedge funds have recently bought and sold shares of the company. LSV Asset Management increased its position in shares of Mallinckrodt by 24.8% in the fourth quarter. LSV Asset Management now owns 2,621,917 shares of the company’s stock worth $59,150,000 after purchasing an additional 520,697 shares during the period. Dimensional Fund Advisors LP increased its position in shares of Mallinckrodt by 16.7% in the third quarter. Dimensional Fund Advisors LP now owns 2,522,330 shares of the company’s stock worth $94,255,000 after purchasing an additional 360,516 shares during the period. Ameriprise Financial Inc. increased its position in shares of Mallinckrodt by 2.6% in the third quarter. Ameriprise Financial Inc. now owns 1,987,196 shares of the company’s stock worth $74,260,000 after purchasing an additional 49,752 shares during the period. Alyeska Investment Group L.P. increased its position in shares of Mallinckrodt by 45.8% in the third quarter. Alyeska Investment Group L.P. now owns 1,535,583 shares of the company’s stock worth $57,385,000 after purchasing an additional 482,591 shares during the period. Finally, Orbimed Advisors LLC increased its position in shares of Mallinckrodt by 15.7% in the third quarter. Orbimed Advisors LLC now owns 1,472,700 shares of the company’s stock worth $55,035,000 after purchasing an additional 200,000 shares during the period. 97.38% of the stock is owned by institutional investors.
Mallinckrodt public limited company develops, manufactures, markets and distributes branded and generic specialty pharmaceutical products and therapies. The Company focuses on various therapeutic areas, such as autoimmune and rare disease specialty areas, including neurology, rheumatology, nephrology, ophthalmology and pulmonology; immunotherapy and neonatal critical care respiratory therapies; analgesics and hemostasis products, and central nervous system drugs.
Receive News & Ratings for Mallinckrodt Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mallinckrodt and related companies with MarketBeat.com's FREE daily email newsletter.